Evidence map›Paper›PMID 32497066›Full record

ArticlePloS one2020

Developmental alterations in the transcriptome of three distinct rodent models of schizophrenia.

Jennifer J Donegan, Angela M Boley, Jeremy P Glenn, Melanie A Carless, Daniel J Lodge

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jennifer J DoneganDepartment of Pharmacology and Center for Biomedical Neuroscience, University of Texas Health Science Center, San Antonio, TX, United States of America.ORCID 0000-0002-7828-2429
Angela M BoleyDepartment of Pharmacology and Center for Biomedical Neuroscience, University of Texas Health Science Center, San Antonio, TX, United States of America.
Jeremy P GlennPopulation Health Program, Texas Biomedical Research Institute, San Antonio, TX, United States of America.
Melanie A CarlessPopulation Health Program, Texas Biomedical Research Institute, San Antonio, TX, United States of America.
Daniel J LodgeDepartment of Pharmacology and Center for Biomedical Neuroscience, University of Texas Health Science Center, San Antonio, TX, United States of America.
The University of Texas Health Science Center at San Antonio · USTexas Biomedical Research Institute · US

Funding

Regulation of ventral hippocampal system functionR01MH090067 · NIMH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LODGE, DANIEL · 2010 to 2019
$3.5M
NRSA Training Core (TL1)TL1TR002647 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHUN, YONG-HEE PATRICIA, FREI, CHRISTOPHER R. · 2018 to 2022
$1.8M
Interneurons differentially regulate discrete pathways from ventral hippocampusR00MH121355 · NIMH · UNIVERSITY OF TEXAS AT AUSTIN · PI DONEGAN, JENNIFER · 2021 to 2023
$825k
Interneurons differentially regulate discrete pathways from ventral hippocampusK99MH121355 · NIMH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DONEGAN, JENNIFER · 2019 to 2020
$239k
NCATS NIH HHS TL1 TR002647NIMH NIH HHS K99 MH121355NIMH NIH HHS R00 MH121355NIMH NIH HHS R01 MH090067
6 · The paper itself

Abstract

Schizophrenia is a debilitating disorder affecting just under 1% of the population. While the symptoms of this disorder do not appear until late adolescence, pathological alterations likely occur earlier, during development in utero. While there is an increasing literature examining transcriptome alterations in patients, it is not possible to examine the changes in gene expression that occur during development in humans that will develop schizophrenia. Here we utilize three distinct rodent developmental disruption models of schizophrenia to examine potential overlapping alterations in the transcriptome, with a specific focus on markers of interneuron development. Specifically, we administered either methylazoxymethanol acetate (MAM), Polyinosinic:polycytidylic acid (Poly I:C), or chronic protein malnutrition, on GD 17 and examined mRNA expression in the developing hippocampus of the offspring 18 hours later. Here, we report alterations in gene expression that may contribute to the pathophysiology of schizophrenia, including significant alterations in interneuron development and ribosome function.

Indexed as

Gene Expression ProfilingGrowth and DevelopmentAnimalsBehavior, AnimalDisease Models, AnimalFemaleHippocampusMalnutritionMethylazoxymethanol AcetatePoly I-CPregnancyRatsRats, Sprague-DawleySchizophreniaMethylazoxymethanol AcetatePoly I-C

Identifiers

PMID32497066
PMCPMC7272013
OpenAlexW3033073571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.